共 245 条
- [11] Bays HE(2017)Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial Cardiovasc Diabetol 16 42-55
- [12] Jones PH(2021)The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial Diabetologia 64 42-774
- [13] McKenney JM(2013)Dapagliflozin effects on the lipid profile of patients with type 2 diabetes mellitus Diabetes 62 A310-413
- [14] Grundy SM(2021)Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus Diabetol Metab Syndr 13 34-103
- [15] Gill EA(2016)Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease Diabetes Obes Metab 18 766-509
- [16] Wild RA(2021)Dapagliflozin does not affect short-term blood pressure variability in patients with type 2 diabetes mellitus Am J Hypertens 34 404-828
- [17] Rao KondapallySeshasai S(2017)Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study Cardiovasc Diabetol 16 84-313
- [18] Kaptoge S(2016)Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade Blood Pressure 25 93-232
- [19] Thompson A(2020)Effects of dapagliflozin on endothelial dysfunction in type 2 diabetes with established ischemic heart disease (EDIFIED) J Endocr Soc. 4 bvz017-268
- [20] Di Angelantonio E(2018)Type-2 diabetes mellitus and cardiovascular disease Future Cardiol 14 491-563